Alpha Teknova clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Alpha Teknova Inc
TKNO · NASDAQ · USD · Market cap $453M · 158 employees
Alpha Teknova, Inc.
Not yet scoredPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price8.21 USD at the 13 Nov 2026 close
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 11.50)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $7.00 to $12.00, base estimate $8.50 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 11.50, read 2026-11-15
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Alpha Teknova Inc holds its Markup at $8.21. The statistical read favours the buyers, held for 12 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 12 days |
| Price at the screen | $8.21 |
| Valuation | N/A trailing · -44.42 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.86 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 27.29% | Below 33% | Interest-bearing debt is just 27.3% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 14.89% | Below 33% | Cash held in interest-bearing accounts and securities is 14.9% of assets, under the one-third limit. | Pass |
| Receivables | 10.17% | Below 49% | Money owed to the company is 10.2% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Alpha Teknova clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Alpha Teknova clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 27%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades at roughly a 3% discount to our $8.50 fair value, none competitive moat, 18.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 3.4% discount to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +4% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere our models see it going: fair-value estimate $8.50, with a range of $7.00 to $12.00, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a none moat. It trades close to our $8.50 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | -44.4x |
| EPS, trailing | -0.31 |
| EPS, forward | -0.19 |
| Revenue growth | +18.5%steady growth |
| Profit margin | -38.4%currently unprofitable |
| Return on equity | -24.2%not currently earning a positive return on equity |
| FCF yield | -0.16% |
| Debt to equity | 0.44minimal debt: a conservative balance sheet |
| Current ratio | 4.49comfortably covers its short-term bills |
| Beta | 0.86steadier than the market |
| Short interest, float | 0.14% |
| 52-week range | 1.91 - 9.48 |
| Moat | NONE |
| Market cap | $453M |
| Employees | 158 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeTKNO trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 18.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 57% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9. Since the last review it dropped out of the Titan Ethical 500.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 34% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9. Since the last review it dropped out of the Titan Ethical 500.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 49% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9. Since the last review it dropped out of the Titan Ethical 500.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 33.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 29.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (3 analysts) rates it none, with a mean price target of $9.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System Yahoo Finance · 2 Oct 2026
- All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy Yahoo Finance · 1 Oct 2026
- Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last? Yahoo Finance · 22 Sep 2026
- Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling Yahoo Finance · 16 Sep 2026
- Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference MarketBeat · 20 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $3.81 | +17.3% | · | $1,173 | +17.3% |
| 2 months | $2.82 | +58.5% | · | $1,585 | +58.5% |
| 3 months | $2.67 | +67.4% | · | $1,674 | +67.4% |
| 6 months | $4.89 | -8.6% | · | $914 | -8.6% |
| 1 year | $5.91 | -24.4% | · | $756 | -24.4% |
| 2 years | $1.76 | +154.0% | · | $2,540 | +154.0% |
| 3 years | $3.89 | +14.9% | · | $1,149 | +14.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TKNO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.